3 days ago · Sage Therapeutics has officially rejected Biogen’s unsolicited takeover bid and will instead undergo a strategic review that could ultimately end up in a transaction of some kind. Sage’s board unanimously rejected the bid, arguing that the proposed $469 million significantly undervalued the company and is not in the best interest of ...

3 days ago · Biogen, which currently holds a 10.2% stake in Sage, proposed to acquire all outstanding Sage shares it does not already own for $7.22 per share. Shares of Sage were up 5.3% at $7.48 in early trading.

2 days ago · BIIB's Recent Offer to Acquire SAGE. Earlier this month, Biogen made an acquisition offer to buy the remaining shares of SAGE that it does not already own for $7.22 per share. The offer price ...

Jan 21, 2025 · Biogen’s offer, at about $469 million, effectively assigns Sage a negative value because the Massachusetts biotech had about $569 million in cash and equivalents at the end of September.

Jan 21, 2025 · Sage Therapeutics last week sued partner Biogen just days after receiving an unsolicited buyout offer from the pharma for nearly $470 million, according to reporting by Bloomberg Law.. The suit, filed in a Delaware court, is sealed, according to Bloomberg, but in a separate court document, Sage noted that it “is seeking preliminary injunctive relief to enforce a standstill agreement and a ...

3 days ago · Sage Therapeutics Inc. is looking for a deal — but it’s not interested in the unsolicited acquisition offer it received earlier this month from longtime partner Biogen Inc.. The Cambridge ...

Sage and Biogen will continue to partner on ZURZUVAE® (zuranolone), the first and only FDA-approved oral treatment for women with postpartum depression (PPD) and will continue to work on their shared vision to help women suffering from PPD.

3 days ago · Sage’s board has stated it will consider “strategic alternatives” to maximise shareholder value. Credit: Bloomberg via Getty Images. Sage Therapeutics has rejected Biogen’s $469m takeover offer, with its board of directors unanimously concluding that …

Jan 10, 2025 · Company Board Concludes the Proposal Significantly Undervalues Sage and Believes it is Not in the Best Interest of Shareholders. ... (“Biogen”) on January 10, 2025, to acquire all outstanding shares of Sage not already owned by Biogen for $7.22 per share. The Company has not set a timetable for the review process, nor has it made any ...

3 days ago · Earlier this month, Biogen offered to purchase Sage’s outstanding shares for an equity value of about $469 million. The drugmaker already owns 10.2% of Sage through a collaboration agreement the ...